Generex Has 180 Days To Regain Listing Compliance
Generex Biotechnology has additional 180 calendar days to regain Nasdaq listing compliance
03:48PM 11/10/09
FDA Allows Emergency Use Of Generex Diabetes Drug
Generex says ruling will allow it to provide Generex Oral-lyn to some patients before approval
06:25PM 09/10/09
Biotech Stock Mailbag: Chelsea Therapeutics
Readers weigh in on Chelsea's rheumatoid arthritis duo, Generex's diabetes spray, AMAG's stock dip, and Anadys' prospects.
08:00AM 07/10/09
China Watch: Yongye Biotechnology
Larry Gilmore, VP of corporate strategy at Yongye Biotechnology, gives an inside look at his company and the agriculture sector in China.
05:00AM 06/17/09
Generex's Net Loss Widens On Interest Expense
Despite surging third quarter revenue, the drug company's net loss increased to $0.08 per share.
01:28PM 06/10/09
Swine Flu Daytrading (RealMoney.com $)
I expect this crisis to be over quick, but here are some ways to play it.
10:58AM 04/27/09
Generex Posts Net Loss in Second Quarter
A large order from the Middle East boosted the company's revenue, but selling expenses and other factors added to the company's net loss.
01:22PM 03/12/09
Biotech Mailbag: Recap on GenVec (RealMoney.com $)
Readers chime in on the its cancer drug. Also, alternative insulin delivery remains a hope.
07:45AM 11/21/08
Feuerstein's Biotech-Stock Mailbag
Glaxo may face a tough sell with newly approved Treximet; additional feedback on Elan, and more.
09:00AM 04/19/08
Feuerstein's Biotech-Stock Mailbag
The latest M&A and what it means more broadly; tapping Russia for drug approvals; the next potential insulin play and more.
10:19AM 04/12/08
Wednesday's Health Winners & Losers
Nektar and MannKind tumble on inhaled insulin drug data.
04:28PM 04/09/08
The software maker hit a 52-week high.
07:06AM 06/13/07



Connect with TheStreet